|
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma
|
|
W21-206-1
|
|
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma
|
|
Dr. Kevin Becker
|
|
This Phase 2 single arm trial in patients with rGBM will determine the efficacy, safety and tolerability and to explore the effectiveness of administering a single dose of an investigational compound called PVSRIPO followed by a drug called pembrolizumab, approximately 14 to 28 days later, in adults diagnosed with a recurrence of a cancerous brain tumor, glioblastoma (rGBM). Study participants will receive a single infusion of PVSRIPO in the hospital, which is delivered to the tumor through a catheter placed in the brain over approximately 6 hours and 30 minutes. Participants will begin receiving intravenous (through a vein) pembrolizumab, between 2 to 4 weeks later. Pembrolizumab infusions are every 3 weeks for up to 24 months. Approximately 6 participants will be accrued to this study for UConn Health.
|
Cancer - Brain, Glioblastoma, Etc.
|
|
|
Check with study contact
|
|
Dr. Kevin Becker. Email: kebecker@uchc.edu or Christopher Sampson. Email: sampson@uchc.edu or Annie Ali. Email: qali@uchc.edu
|
|
Enrolling/recruiting. For current recruitment status, please check with study contact.
|
|
clinicaltrials.gov/ct2/show/NCT04479241
|
|
|